The impact of treatment on lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) progression

European Urology, Supplements

Volumn 3, Issue 4, 2004, Pages 12-17

  Berges, Richard ^a  

^a PAN Klinik am Neumarkt   (Germany)

Author keywords

Acute urinary retention; Benign prostatic hyperplasia; Disease progression; Lower urinary tract symptoms; Quality of life; Surgery; Therapy; Tolerability

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PRAZOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ASTHENIA; CLINICAL TRIAL; DISEASE COURSE; DIZZINESS; DRUG EFFECT; DRUG TOLERABILITY; DYSPNEA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; IMPOTENCE; LIBIDO DISORDER; MEDICAL DECISION MAKING; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PERIPHERAL EDEMA; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SYMPTOM; SYNCOPE; TREATMENT FAILURE; URINARY TRACT DISEASE; URINE RETENTION; UROLOGIC SURGERY;

EID: 4544312082     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2004.08.003     Document Type: Article

References (33)

1. Artibani W. Integrating the patient risk profile in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Eur Urol Suppl 2004;3(4):1-6.
2. Lowe FC. Patient risk profiles for progression of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Eur Urol Suppl 2004;3(4):7-11.
3. M.J. Speakman Lower urinary tract symptoms suggestive of benign prostatic obstruction: what is the available evidence for rational management? Eur Urol. 39 Suppl 3 2001 6 12
4. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003;170:530-547.
5. Chatelain C, Denis L, Foo JKT, Khoury S, McConnell J, Abrams P, et al., and the members of the committees. 5th International Consultation on BPH. Recommendations of the International Scientific Committee: evaluation and treatment of lower urinary tract symptoms (LUTS) in older men. In: Chatelain C, Denis L, Foo KT, Khoury S, McConnell J, editors. Benign Prostatic Hyperplasia, 5th International Consultation on Benign Prostatic Hyperplasia (BPH), June 25-28, 2000 Paris. Plymouth: Plymbridge Distributors Ltd; 2001. p. 519-34.
6. J.D. McConnell, C.G. Roehrborn, O.M. Bautista, G.L. Andriole, C.M. Dixon, J.W. Kusek for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med. 349 2003 2387 2398
7. C.R. Chapple BHP Disease Management. Introduction and concluding remarks Eur Urol. 36 Suppl 3 1999 1 6
8. 1-adrenoceptor antagonists for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): state of the art. Eur Urol 2004;3(4):23-30.
9. B. Djavan, and M. Marberger A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction Eur Urol. 36 1999 1 13
10. P. van Kerrebroeck, A. Jardin, P. van Cangh, and K.U. Laval Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study Eur Urol. 41 2002 54 61
11. C.C. Schulman, T.M. Lock, J.M. Buzelin, F. Boeminghaus, T.P. Stephenson, and M. Talja Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia J Urol. 166 2001 1358 1363
12. A. Jardin, H. Bensadoun, M.C. Delauche-Cavallier, and P. Attali Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey Br J Urol 74 1994 579 584
13. H. Lepor for the Terazosin Research Group Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia Urology 45 1995 406 413
14. H. Lepor, S.A. Kaplan, I. Klimberg, D.F. Mobley, A. Fawzy, and M. Gaffney Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients J Urol. 157 1997 525 530
15. P. Narayan, C.P. Evans, and T. Moon Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia J Urol. 170 2003 498 502
16. H. Lepor, W.O. Williford, M.J. Barry, M.K. Brawer, C.M. Dixon, and G. Gormley The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia N Engl J Med. 335 1996 533 539
17. F.M.J. Debruyne, A. Jardin, D. Colloi, L. Resel, W.P. Witjes, and M.C. Delauche-Cavallier Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia Eur Urol. 34 1998 169 175
18. R.S. Kirby, C. Roehrborn, P. Boyle, G. Bartsch, A. Jardin, and M.M. Cary Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial Urology 61 2003 119 126
19. P. Rigatti, M. Brausi, R.M. Scarpa, D. Porru, H. Schumacher, C.A. Rizzi for the MICTUS study group A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia Prostate Cancer Prostatic Diseases 6 2003 315 323
20. C.G. Roehrborn, J.D. McConnell, J.W. Kusek, L.M. Nyberg, K.M. Slawin, K.T. McVary and the MTOPS Investigator Group Impact of baseline PSA and TRUS volume on longitudinal changes in IPSS and maximum flow rate in MTOPS J Urol. 171 2004 241 [Abstract 911]
21. M.C. Michel Protecting bladder function and reducing disease progression Eur Urol Suppl. 2 7 2003 13 18
22. J.D. McConnell, R. Bruskewitz, P. Walsh, G. Andriole, M. Lieber, and H.L. Holtgrewe The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia New Engl J Med. 338 1998 557 563
23. C.G. Roehrborn, P. Boyle, J.C. Nickel, K. Höfner, and G.L. Andriole Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia Urology 60 2002 434 441
24. S.A. Kaplan, C.G. Roehrborn, J.D. McConnell, K.J. Kreder, M.J. Lieber, and S.C. Jacobs Baseline symptoms, uroflow, and post-void residual urine as predictors of BPH clinical progression in medically treated arms of the MTOPS trial J Urol. 169 4 Suppl 2003 332 [Abstract 1289]
25. M. Speakman, R. Snijder, and C. Doyle Tamsulosin-treated patients have a low risk of developing acute urinary retention which is well maintained over time Eur Urol Suppl. 3 2 2004 90 [Abstract 350]
26. J. Speakman, J.R. Snijder, G.L. Anthonijs, and C.A. Doyle Baseline prostatic specific antigen does not affect the efficacy of tamsulosin in patients with lower urinary tract symptoms/benign prostatic hyperplasia Eur Urol Suppl. 2 1 2003 159 [Abstract 625]
27. G.M. Clifford, J. Logie, and R.D.T. Farmer How do symptoms indicative of BPH progress in real life practice? The UK experience Eur Urol. 38 Suppl 1 2000 48 53
28. R. Berges Impact of therapy used in clinical practice on LUTS/BPH disease progression Eur Urol Suppl 2 7 2003 19 24
29. K.M.C. Verhamme, J.P. Dieleman, G.S. Bleumink, and J. van der Lei Sturkenboom MCJM, for the Triump Pan European Expert Panel. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care: the Triumph project Eur Urol. 42 2002 323 328
30. Farmer R, Logie J, Clifford G. The effectiveness of medical treatments in delaying the need for surgery among men with LUTS/BPH - a population study. Presented during the 26th Congress of the Société Internationale d'Urologie (SIU), Stockholm, 8-12 September 2002. BJU Int. 2002;90(Suppl 2):15 [Abstract P.1.2.13].
31. Verhamme KMC, Dieleman JP, Bleumink GS, van der Lei J, Stricker BhCh, Sturkenboom M. The use of α-blockers and 5-α reductase inhibitors decreases the risk of prostatic surgery for patients diagnosed with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Presented during the 18th International Conference on PharmacoEpidemiology, 18-21 August 2002. Edingburgh [Abstract 233].
32. J.J.W. Logie, G.M. Clifford, R.D. Farmer, and B.P. Meesen Lower urinary tract symptoms suggestive of benign prostatic obstruction - Triumph: the role of general practice databases Eur Urol. 39 Suppl 3 2001 42 47
33. J.J. De la Rosette, B.B. Kortmann, C. Rossi, G.S. Sonke, D.L. Floratos, and L.A. Kiemeney Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms J Urol. 167 2002 1734 1739